{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:02:40Z","timestamp":1770926560278,"version":"3.50.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1185\/030079902125000813","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T18:06:28Z","timestamp":1033495588000},"page":"258-264","source":"Crossref","is-referenced-by-count":124,"title":["Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series"],"prefix":"10.1185","volume":"18","author":[{"given":"R.","family":"Bullock","sequence":"first","affiliation":[{"name":"Victoria Hospital, Swindon, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cameron","sequence":"additional","affiliation":[{"name":"William Harvey Hospital, Ashford, Kent, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025628925796"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/111.3.525"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3932(01)00099-9"},{"key":"e_1_2_1_5_1","first-page":"174","volume-title":"The Neuropathology of Dementia","author":"Esiri MM","year":"1997","unstructured":"Esiri MM, McShane RH. Parkinson\u2019s disease and dementia. In Esiri M, Morris JH, eds. The Neuropathology of Dementia. Cambridge: Cambridge University Press, 1997:174\u201393"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530360060019"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.1.11"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6855.673"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.61.3.324-a"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03399-7"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912040-00005"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000047952"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990152673800"},{"issue":"1","key":"e_1_2_1_14_1","first-page":"P0143","article-title":"Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: differential effects across time","volume":"187","author":"Almkvist O","year":"2001","unstructured":"Almkvist O, Darreh-Shori T, Spiegel R, Nordberg A. Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: differential effects across time. J Neurol Sci 2001;187(Suppl 1):P0143","journal-title":"J Neurol Sci"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200201210-00020"},{"key":"e_1_2_1_16_1","unstructured":"Giacobini E Spiegel R Enz A Veroff AE Cutler NR. Inhibition of acetyl and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer\u2019s disease by rivastigmine: correlation with cognitive benefit. J Neural Trans in press"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1204"},{"key":"e_1_2_1_18_1","article-title":"Rivastigmine in the treatment of parkinsonian hallucinosis","volume":"67","author":"Reading PJ","year":"1999","unstructured":"Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian hallucinosis. J Neurol Neurosurg Psychiatry 1999;67:265 (Abstr)","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048651"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta5010"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.599"},{"key":"e_1_2_1_22_1","unstructured":"Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract 2002 in press"},{"key":"e_1_2_1_23_1","first-page":"55","article-title":"for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease","volume":"1","author":"Corey-Bloom J","year":"1998","unstructured":"Corey-Bloom J, Anand R, Veach J, for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease. Int J Geriatr Psychopharmacol 1998;1: 55\u201365","journal-title":"Int J Geriatr Psychopharmacol"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.633"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2000.00046.x"},{"key":"e_1_2_1_26_1","unstructured":"Moretti R Torre P Antonello RM Cazzato G Bava A. Treatment of symptoms specific to patients with subcortical vascular dementia: an open label pilot study comparing rivastigmine and cardioaspirin. Curr Ther Res in press"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17150"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610298005341"},{"issue":"2","key":"e_1_2_1_29_1","first-page":"P\u2013123","article-title":"Donepezil in dementia with Lewy bodies: treatment and withdrawal","volume":"13","author":"Sanders J","year":"2001","unstructured":"Sanders J, Newby VJ, Richardson JP. Donepezil in dementia with Lewy bodies: treatment and withdrawal. Int Psychogeriatr 2001;13(Suppl 2):P\u2013123","journal-title":"Int Psychogeriatr"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17355"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017126"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400410"},{"key":"e_1_2_1_34_1","first-page":"9","volume-title":"The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer\u2019s disease patients: a 12-week, multinational, comparative study","author":"Bullock R","year":"2001","unstructured":"Bullock R, Passmore P, Potocnik F, Hock C. The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer\u2019s disease patients: a 12-week, multinational, comparative study. Poster presented at the American Geriatrics Society (AGS) Annual Meeting, Chicago, USA, 9\u201313 May, 2001"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.3.406"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1993.10"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079902125000813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:03:22Z","timestamp":1770923002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079902125000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1185\/030079902125000813"],"URL":"https:\/\/doi.org\/10.1185\/030079902125000813","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}